Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes

European Respiratory Journal

Volumn 44, Issue 4, 2014, Pages 985-993

  Su, Robert ^a   Li, Michael M ^b   Bhakta, Nirav R ^b   Solberg, Owen D ^b   Darnell, Eli P B ^b   Ramstein, Joris ^b   Garudadri, Suresh ^b   Ho, Melissa ^b   Woodruff, Prescott G ^a,b   Koth, Laura L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL9 CHEMOKINE; INTERFERON; RNA; T LYMPHOCYTE RECEPTOR; TRANSCRIPTOME;

ADULT; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FORCED VITAL CAPACITY; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IMMUNE SYSTEM; LONGITUDINAL STUDY; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PATTERN RECOGNITION; PHENOTYPE; RNA PROCESSING; SARCOIDOSIS; TRANSCRIPTOMICS; TREATMENT OUTCOME; UPREGULATION; AGED; BLOOD; GENETICS; MIDDLE AGED;

ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SARCOIDOSIS; TRANSCRIPTOME;

EID: 84907551546     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00039714     Document Type: Article

References (36)

1. Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
2. Chen ES, Moller DR. Sarcoidosis -scientific progress and clinical challenges. Nat Rev Rheumatol 2011; 7: 457-467.
3. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014; 383: 1155-1167.
4. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802.
5. Judson MA, Baughman RP, Costabel U, et al. Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial. Eur Respir J 2008; 31: 1189-1196.
6. Baughman RP, Lower EE, Drent M. Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them. Sarcoidosis Vasc Diffuse Lung Dis 2008; 25: 76-89.
7. Koth LL, Solberg OD, Peng JC, et al. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. Am J Respir Crit Care Med 2011; 184: 1153-1163.
8. Tzouvelekis A, Kouliatsis G, Anevlavis S, et al. Serum biomarkers in interstitial lung diseases. Respir Res 2005; 6: 78.
9. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338.
11. Neville E, Walker AN, James DG. Prognostic factors predicting the outcome of sarcoidosis: an analysis of 818 patients. Q J Med 1983; 52: 525-533.
12. Pabst S, Baumgarten G, Stremmel A, et al. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clin Exp Immunol 2006; 143: 420-426.
13. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115: 1158-1165.
14. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999; 54: 742-746.
15. Su R, Nguyen ML, Agarwal MR, et al. Interferon-inducible chemokines reflect severity and progression in sarcoidosis. Respir Res 2013; 14: 121.
16. Grunewald J, Berlin M, Olerup O, et al. Lung T-helper cells expressing T-cell receptor AV2S3 associate with clinical features of pulmonary sarcoidosis. Am J Respir Crit Care Med 2000; 161: 814-818.
17. Mitchell DN, Scadding JG. Sarcoidosis. London, Hodder Arnold, 2012.
18. Gottlieb JE, Israel HL, Steiner RM, et al. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997; 111: 623-631.
19. Crouser ED, Culver DA, Knox KS, et al. Gene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis. Am J Respir Crit Care Med 2009; 179: 929-938.
20. Rosenbaum JT, Pasadhika S, Crouser ED, et al. Hypothesis: sarcoidosis is a STAT1-mediated disease. Clin Immunol 2009; 132: 174-183.
21. Takeuchi M, Oh IK, Suzuki J, et al. Elevated serum levels of CXCL9/monokine induced by interferon-c and CXCL10/interferon-c-inducible protein-10 in ocular sarcoidosis. Invest Ophthalmol Vis Sci 2006; 47: 1063-1068.
22. Woodruff PG, Modrek B, Choy DF, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 2009; 180: 388-395.
23. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007; 104: 15858-15863.
24. Bhakta NR, Solberg OD, Nguyen CP, et al. A qPCR-based metric of Th2 airway inflammation in asthma. Clin Transl Allergy 2013; 3: 24.
25. Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 2002; 16: 61-71.
26. Crouser ED, Lozanski G, Fox CC, et al. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to antitumor necrosis factor-A therapy. Chest 2010; 137: 1432-1435.
27. Morell F, Levy G, Orriols R, et al. Delayed cutaneous hypersensitivity tests and lymphopenia as activity markers in sarcoidosis. Chest 2002; 121: 1239-1244.
28. Sweiss NJ, Salloum R, Gandhi S, et al. Significant CD4, CD8, and CD19 lymphopenia in peripheral blood of sarcoidosis patients correlates with severe disease manifestations. PLoS One 2010; 5: e9088.
29. Maertzdorf J, Weiner J 3rd., Mollenkopf HJ., et al. Common patterns and disease-related signatures in tuberculosis and sarcoidosis. Proc Natl Acad Sci USA 2012; 109: 7853-7858.
30. Ziegenhagen MW, Benner UK, Zissel G, et al. Sarcoidosis: TNF-A release from alveolar macrophages and serum level of sIL-2R are prognostic markers. Am J Respir Crit Care Med 1997; 156: 1586-1592.
31. Moller DR, Chen ES. Genetic basis of remitting sarcoidosis: triumph of the trimolecular complex?Am J Respir Cell Mol Biol 2002; 27: 391-395.
32. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-c and tumor necrosis factor-A in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kB. J Biol Chem 1997; 272: 14899-14907.
33. Nishioka Y, Manabe K, Kishi J, et al. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol 2007; 149: 317-326.
34. Agostini C, Cassatella M, Zambello R, et al. Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. J Immunol 1998; 161: 6413-6420.
35. Oswald-Richter KA, Richmond BW, Braun NA, et al. Reversal of global CD4+ subset dysfunction is associated with spontaneous clinical resolution of pulmonary sarcoidosis. J Immunol 2013; 190: 5446-5453.
36. Prasse A, Katic C, Germann M, et al. Phenotyping sarcoidosis from a pulmonary perspective. Am J Respir Crit Care Med 2008; 177: 330-336.